Compounds for the treatment of HIV

US10370358B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10370358-B2
Application numberUS-201815902883-A
CountryUS
Kind codeB2
Filing dateFeb 22, 2018
Priority dateJul 6, 2011
Publication dateAug 6, 2019
Grant dateAug 6, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.

First claim

Opening claim text (preview).

What is claimed is: 1. A method for treating an HIV infection in a human, comprising administering a compound of formula I: or a pharmaceutically acceptable salt thereof, to the human, wherein: A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein any pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl of A is substituted with one Z 1 group and optionally substituted with 1, 2, or 3 Z 2 groups; B is absent; or B is —O − and the nitrogen to which the —O − group is attached is N + ; W is —CR 3a R 3b —; R 1 is a bicyclic-heteroaryl, tricyclic-heteroaryl, bicyclic-heterocycle or tricyclic-heterocycle, wherein any bicyclic-heteroaryl, tricyclic-heteroaryl, bicyclic-heterocycle or tricyclic-heterocycle of R 1 is optionally substituted with 1, 2, 3, 4, or 5 Z 3 groups; R 2 is a 6-membered aryl, 5-membered heteroaryl or 6-membered heteroaryl, wherein any 6-membered aryl, 5-membered heteroaryl or 6-membered heteroaryl of R 2 is optionally substituted with 1, 2, or 3 Z 4 groups; each R 3a and R 3b is independently selected from H, (C 1 -C 6 )alkyl, (C 1 -C 3 )haloalkyl, (C 1 -C 6 )heteroalkyl, heterocyclyl(C 1 -C 6 )alkyl-; each Z 1 is independently selected from (C 2 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 3 -C 7 )carbocycle, (C 6 -C 20 )aryl, heteroaryl, heterocycle and —OR n1 , wherein any (C 3 -C 7 )carbocycle, (C 6 -C 20 )aryl, heteroaryl and heterocycle of Z 1 is optionally substituted with 1, 2, 3, 4, or 5 Z 1a or Z 1b groups and wherein any (C 2 -C 8 )alkyl, (C 2 -C 8 )alkenyl and (C 2 -C 8 )alkynyl of Z 1 is optionally substituted with 1, 2, 3, 4, or 5 Z 1a groups; each Z 1a is independently selected from (C 3 -C 7 )carbocycle, (C 6 -C 20 )aryl, heteroaryl, heterocycle, halogen, —CN, —OR n2 , —OC(O)R p2 , —OC(O)NR q2 R r2 , —SR n2 , —S(O)R p2 , —S(O) 2 OH, —S(O) 2 R p2 , —S(O) 2 NR q2 R r2 , —NR q2 R r2 , —NR n2 COR p2 , —NR n2 CO 2 R p2 , —NR n2 CONR q2 R r2 , —NR n2 S(O) 2 R p2 , —NR n2 S(O) 2 OR p2 , —NR p2 S(O) 2 NR q2 R r2 , NO 2 , —C(O)R n2 , —C(O)OR n2 , —C(O)NR q2 R r2 and —S(O) 2 NR n2 COR p2 , wherein any (C 3 -C 7 )carbocycle, (C 6 -C 20 )aryl, heteroaryl and heterocycle of Z 1a is optionally substituted with 1, 2, 3, 4, or 5 Z 1c or Z 1d groups; each Z 1b is independently selected from (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl and (C 2 -C 8 )alkynyl, wherein any (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl and (C 2 -C 8 )alkynyl of Z 1b is optionally substituted with 1, 2, 3, 4, or 5 Z 1c groups; each Z 1c is independently selected from (C 3 -C 7 )carbocycle, (C 6 -C 20 )aryl, heteroaryl, heterocycle, halogen, —CN, —OR n3 , —OC(O)R p3 , C(O)NR q3 R r3 , —SR n3 , —S(O)R p3 , —S(O) 2 OH, —S(O) 2 R p3 , —S(O) 2 NR q3 R r3 , —NR q3 R r3 , —NR n3 COR p3 , —NR n3 CO 2 R p3 , —NR n3 ONR q3 R r3 , —NR n3 S(O) 2 R p3 , —NR n3 S(O) 2 OR p3 , —NR n3 S(O 2 NR q3 R r3 , NO 2 , —C(O)R n3 , —C(O)OR n3 , —C(O)NR q3 R r3 , (C 6 -C 20 )haloaryl, haloheteroaryl, haloheterocycle and (C 1 -C 8 )heteroalkyl; each Z 1d is independently selected from (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl and (C 1 -C 8 )haloalkyl; each R n1 is independently selected from (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 3 -C 7 )carbocycle, heterocycle, heteroaryl and (C 6 -C 20 )aryl, wherein any (C 3 -C 7 )carbocycle, (C 6 -C 20 )aryl, heteroaryl and heterocycle of R n1 is optionally substituted with 1, 2, 3, 4, or 5 Z 1a or Z 1b groups, and wherein any (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl and (C 2 -C 8 )alkynyl of R n1 is optionally substituted with 1, 2, 3, 4, or 5 Z 1a groups; each R n2 is independently selected from H, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 3 -C 7 )carbocycle, heterocycle, heteroaryl and (C 6 -C 20 )aryl, wherein any (C 3 -C 7 )carbocycle, (C 6 -C 20 )aryl, heteroaryl and heterocycle of R n2 is optionally substituted with 1, 2, 3, 4, or 5 Z 1c or Z 1a groups, and wherein any (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl and (C 2 -C 8 )alkynyl of R n2 is optionally substituted with 1, 2, 3, 4, or 5 Z 1c groups; each R p2 is independently selected from (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 3 -C 7 )carbocycle, heterocycle, heteroaryl and (C 6 -C 20 )aryl, wherein any (C 3 -C 7 )carbocycle, (C 6 -C 20 )aryl, heteroaryl and heterocycle of R p2 is optionally substituted with 1, 2, 3, 4, or 5 Z 1c or Z 1a groups, and wherein any (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl and (C 2 -C 8 )alkynyl of R p2 is optionally substituted with 1, 2, 3, 4, or 5 Z 1c groups; R q2 and R r2 are each independently selected from H, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 3 -C 7 )carbocycle, heterocycle, heteroaryl and (C 6 -C 20 )aryl, wherein any (C 3 -C 7 )carbocycle, (C 6 -C 20 )aryl, heteroaryl and heterocycle of R q2 or R r2 is optionally substituted with 1, 2, 3, 4, or 5 Z 1c or Z 1d groups, and wherein any (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl and (C 2 -C 8 )alkynyl of R q2 or R r2 is optionally substituted with 1, 2, 3, 4, or 5 Z 1c groups, or R q2 and R r2 together with the nitrogen to which they are attached form a 5, 6 or 7-membered heterocycle, wherein the 5, 6 or 7-membered heterocycle is optionally substituted with 1, 2, 3, 4 or 5 Z 1c or Z 1d groups; each R n3 is independently selected from H, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 3 -C 7 )carbocycle, heterocycle, heteroaryl, (C 6 -C 20 )aryl, (C 6 -C 20 )haloaryl, haloheteroaryl, haloheterocycle, (C 1 -C 8 )haloalkyl and (C 1 -C 8 )heteroalkyl; each R p3 is independently selected from (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 3 -C 7 )carbocycle, heterocycle, heteroaryl, (C 6 -C 20 )aryl, (C 6 -C 20 )haloaryl, haloheteroaryl, haloheterocycle, (C 1 -C 8 )haloalkyl and (C 1 -C 8 )heteroalkyl; R q3 and R r3 are each independently selected from H, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 3 -C 7 )carbocycle, heterocycle, heteroaryl, (C 6 -C 20 )aryl, haloaryl, haloheteroaryl, haloheterocycle, (C 1 -C 8 )haloalkyl and (C 1 -C 8 )heteroalkyl, or R q3 and R r3 together with the nitrogen to which they are attached form a 5, 6 or 7-membered heterocycle; each Z 2 is independently selected from (C 1 -C 6 )alkyl, (C 1 -C 6 )haloalkyl, (C 3 -C 7 )carbocycle, halogen, CN, OH and —O(C 1 -C 6 )alkyl; each Z 3 is independently selected from (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 3 -C 7 )carbocycle, (C 6 -C 20 )aryl, halogen, —CN, —OR n4 , —S(O)R p4 , —NR n4 CO 2 R p4 , —NR n4 S(O) 2 R p4 , —C(O)R n4 , —C(O)OR n4 , —C(O)NR q4 R r4 and —B(OR q4 )(OR r4 ) wherein any (C 3 -C 7 )carbocycle and (C 6 -C 20 )aryl of Z 3 is optionally substituted with 1, 2, 3, 4, or 5 Z 3a or Z 3b groups, and wherein any (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl and (C 2 -C 8 )alkynyl of Z 3 is optionally substituted with 1, 2, 3, 4, or 5 Z 3a groups; each Z 3a is independently selected from (C 3 -C 7 )carbocycle, (C 6 -C 20 )aryl, heteroaryl, heterocycle, halogen, —CN, —OR n5 , —OC(O)R p5 , —OC(O)NR q5 R r5 , —SR n5 , —S(O)R p5 , —S(O) 2 OH, —S(O) 2 R p5 , —S(O) 2 NR q5 R r5 , —NR q5 R r5 , —NR n5 COR p5 , —NR n5 CO 2 R p5 , —NR n5 CONR q5 R r5 , —NR n5 S(O) 2 R p5 , —NR n5 S(O) 2 OR p5 , —NR n5 S(O) 2 NR q5 R r5 , NO 2 , —C(O)R n5 , —C(O)OR n5 , and —C(O)NR q5 R r5 , wherein any (C 3 -C 7 )carbocycle, (C 6 -C 20 )aryl, heteroaryl and heterocycle of Z 1a is optionally substituted with 1, 2, 3, 4, or 5 Z 3c or Z 3d groups; each Z 3b is independently selected from (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl and (C 2 -C 8 )alkynyl, wherein any (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl and (C 2 -C 8 )alkynyl of Z 3b is optionally substituted with 1, 2, 3, 4, or 5 Z 3c groups; each Z 3c is independently selected from (C 3 -C 7 )carbocycle, (C 6 -C

Assignees

Inventors

Classifications

  • Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

  • for HIV · CPC title

  • for RNA viruses · CPC title

  • Non-condensed quinolines and containing further heterocyclic rings · CPC title

  • C07D401/12Primary

    linked by a chain containing hetero atoms as chain links · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10370358B2 cover?
The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HI…
Who is the assignee on this patent?
Gilead Sciences Inc
What technology area does this patent fall under?
Primary CPC classification C07D401/12. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).